TY - JOUR
T1 - Clinical significance of serum soluble interleukin 2 receptor-α in esophageal squamous cell carcinoma
AU - Wang, Liang Shun
AU - Chow, Kuan Chih
AU - Li, Wing Yin
AU - Liu, Chia Chuan
AU - Wu, Yu-Chung
AU - Huang, Min Hsiung
PY - 2000/4
Y1 - 2000/4
N2 - Although the serum level of soluble interleukin-2 receptor α (sIL-2Rα) has been shown to correlate with progression and prognosis of several cancers, data to support its clinical significance to esophageal squamous cell carcinoma (ESCC) are limited. This study was conducted to assess the prognostic value and source of sIL-2Rα in patients with ESCC. From January 1986 to June 1997, 125 patients with histopathologically confirmed ESCC were enrolled for study. Ninety-three patients underwent en bloc esophagectomy, and 32 patients with unresectable tumor underwent palliative surgery. Four (4.3%; 4 of 93) patients died of surgical complications. Serum levels of sIL- 2Rα were measured by ELISA. Expression of IL-2Rα, IL-2Rβ, and IL-2Rγ in the pathological section was determined, respectively, by immunohistochemistry (IHC) and in situ hybridization (ISH). Compared with the healthy control group (1020 ± 476 pg/ml, n = 103), ESCC patients tended to have significantly higher serum sIL-2Rα concentrations (1424 ± 798 pg/ml, n = 121). The sIL-2Rα level was correlated with age, Tumor-Node-Metastasis classification, tumor stage, reading score of the IHC staining, and survival but not with the pathological grade or lymphovascular invasion. Prognosis was worse for patients with high sIL-2Rα levels (≥1500 pg/ml) than for those with low serum sIL-2Rα levels (< 1500 pg/ml; P = 0.0209). It can be used as an independent prognostic factor of ESCC. In the pathological sections, expression of IL-2Rα, IL-2Rβ, and IL-2Rγ was detected in 17 (18.1%), 83 (89.2%), and 83 (89.2%) cases, respectively, by IHC, and the message of IL- 2Rα was identified in tumor cells by ISH in 30.1% (28 of 93) of the cases. Serum concentrations of sIL-2Rα are frequently elevated in ESCC patients and are correlated with disease progression and survival. These data indicate that, in addition to activated T cells, cancer cells could be an important source of sIL-2Rα in ESCC patients.
AB - Although the serum level of soluble interleukin-2 receptor α (sIL-2Rα) has been shown to correlate with progression and prognosis of several cancers, data to support its clinical significance to esophageal squamous cell carcinoma (ESCC) are limited. This study was conducted to assess the prognostic value and source of sIL-2Rα in patients with ESCC. From January 1986 to June 1997, 125 patients with histopathologically confirmed ESCC were enrolled for study. Ninety-three patients underwent en bloc esophagectomy, and 32 patients with unresectable tumor underwent palliative surgery. Four (4.3%; 4 of 93) patients died of surgical complications. Serum levels of sIL- 2Rα were measured by ELISA. Expression of IL-2Rα, IL-2Rβ, and IL-2Rγ in the pathological section was determined, respectively, by immunohistochemistry (IHC) and in situ hybridization (ISH). Compared with the healthy control group (1020 ± 476 pg/ml, n = 103), ESCC patients tended to have significantly higher serum sIL-2Rα concentrations (1424 ± 798 pg/ml, n = 121). The sIL-2Rα level was correlated with age, Tumor-Node-Metastasis classification, tumor stage, reading score of the IHC staining, and survival but not with the pathological grade or lymphovascular invasion. Prognosis was worse for patients with high sIL-2Rα levels (≥1500 pg/ml) than for those with low serum sIL-2Rα levels (< 1500 pg/ml; P = 0.0209). It can be used as an independent prognostic factor of ESCC. In the pathological sections, expression of IL-2Rα, IL-2Rβ, and IL-2Rγ was detected in 17 (18.1%), 83 (89.2%), and 83 (89.2%) cases, respectively, by IHC, and the message of IL- 2Rα was identified in tumor cells by ISH in 30.1% (28 of 93) of the cases. Serum concentrations of sIL-2Rα are frequently elevated in ESCC patients and are correlated with disease progression and survival. These data indicate that, in addition to activated T cells, cancer cells could be an important source of sIL-2Rα in ESCC patients.
UR - http://www.scopus.com/inward/record.url?scp=0034007146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034007146&partnerID=8YFLogxK
M3 - Article
C2 - 10778976
AN - SCOPUS:0034007146
SN - 1078-0432
VL - 6
SP - 1445
EP - 1451
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -
